S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

JNJ Johnson and Johnson

144.29

-0.33 (-0.23%)

Jan 02 2025 - Closed

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
Thursday 2 January 2025 (19 hours ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 12 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Thursday 12 December 2024 (3 weeks ago) • Business Wire

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Tuesday 10 December 2024 (3 weeks ago) • Business Wire

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
Monday 9 December 2024 (3 weeks ago) • PR Newswire (US)

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
Monday 9 December 2024 (4 weeks ago) • PR Newswire (US)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
Sunday 8 December 2024 (4 weeks ago) • PR Newswire (US)

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
Sunday 8 December 2024 (4 weeks ago) • PR Newswire (US)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
Sunday 8 December 2024 (4 weeks ago) • PR Newswire (US)

Form 144 - Report of proposed sale of securities
Wednesday 4 December 2024 (4 weeks ago) • Edgar (US Regulatory)

More Johnson and Johnson News Articles

ABN AMRO International b...

Dev.bk.j. 25unr

SG Issuer Sg Issuer Mc D...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions